10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

MERCK & CO., INC.

Ticker: MRK   Fiscal Year: 2010

Consolidated Statement of Income

Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2010Dec 31, 2009Dec 31, 2008
Sales
$
45,987
27,42823,850
 
Costs, Expenses and Other
Materials and production18,3969,0195,583
Marketing and administrative13,2458,5437,377
Research and development10,9915,8454,805
Restructuring costs9851,6341,033
Equity income from affiliates(587)(2,235)(2,561)
Other (income) expense, net1,304(10,668)(2,318)
Total Costs, Expenses and Other44,33412,13813,919
 
Income Before Taxes1,65315,2909,931
Taxes on Income6712,2681,999
 
Net Income98213,0227,932
 
Less: Net Income Attributable to Noncontrolling Interests121123124
Net Income Attributable to Merck & Co., Inc.86112,8997,808
 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders0.285.673.65
 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders0.285.653.63
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

MERCK & CO., INC.

Ticker: MRK   Fiscal Year: 2010

Consolidated Statement of Cash Flows

Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2010Dec 31, 2009Dec 31, 2008
Cash Flows from Operating Activities
Net income
$
982
13,0227,932
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization7,3812,5761,631
In-process research and development impairment charges2,441
Gains on distributions from AstraZeneca LP(443)(2,223)
Gain related to Merck/Schering-Plough partnership(7,530)
Gain on disposition of interest in Merial Limited(3,163)
Equity income from affiliates(587)(2,235)(2,561)
Dividends and distributions from equity affiliates3241,7244,290
Deferred income taxes(1,092)1,821530
Share-based compensation509415348
Other377(535)608
Net changes in assets and liabilities:
Accounts receivable(1,089)165(889)
Inventories1,9901,211(452)
Trade accounts payable124(45)
Accrued and other current liabilities35(4,003)(1,711)
Income taxes payable128(365)(465)
Noncurrent liabilities(98)231(108)
Other(160)103(358)
Net Cash Provided by Operating Activities10,8223,3926,572
 
Cash Flows from Investing Activities
Capital expenditures(1,678)(1,461)(1,298)
Purchases of securities and other investments(7,197)(3,071)(11,967)
Proceeds from sales of securities and other investments4,56110,94211,066
Proceeds from sale of interest in Merial Limited4,000
Schering-Plough merger, net of cash acquired(12,843)
Acquisitions of businesses, net of cash acquired(256)(130)
Distributions from AstraZeneca LP6471,899
Decrease (Increase) in restricted assets2765,548(1,630)
Other15017196
Net Cash (Used in) Provided by Investing Activities(3,497)3,156(1,834)
 
Cash Flows from Financing Activities
Net change in short-term borrowings90(2,422)1,860
Proceeds from issuance of debt1,9994,228
Payments on debt(1,341)(25)(1,392)
Purchases of treasury stock(1,593)(2,725)
Dividends paid to stockholders(4,734)(3,215)(3,279)
Other dividends paid(119)(264)(122)
Proceeds from exercise of stock options363186102
Other(106)(126)33
 
Net Cash Used in Financing Activities(5,441)(1,638)(5,523)
 
Effect of Exchange Rate Changes on Cash and Cash Equivalents(295)33(183)
 
Net Increase (Decrease) in Cash and Cash Equivalents1,5894,943(968)
Cash and Cash Equivalents at Beginning of Year9,3114,368
Cash and Cash Equivalents at End of Year10,9009,3114,368
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

MERCK & CO., INC.

Ticker: MRK   Fiscal Year: 2010

Consolidated Balance Sheet

Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011)

(In Millions, except shares in actual)
 As ofAs of
 Dec 31, 2010Dec 31, 2009
Assets
Current Assets
Cash and cash equivalents
$
10,900
9,311
Short-term investments1,301293
Accounts receivable (net of allowance for doubtful accounts of $104 in 2010 and $113 in 2009)7,3446,603
Inventories (excludes inventories of $1,194 in 2010 and $1,157 in 2009 classified in Other assets - see Note 8)5,8688,048
Deferred income taxes and other current assets3,6514,177
 
Total current assets29,06428,432
 
Investments2,175432
 
Property, Plant and Equipment (at cost)
Land658667
Buildings11,94512,231
Machinery, equipment and office furnishings15,89416,158
Construction in progress2,0661,818
 
Property, Plant and Equipment, Gross30,56330,874
Less allowance for depreciation13,48112,595
 
Property, Plant and Equipment, Net17,08218,279
 
Goodwill12,37812,038
 
Other Intangibles, Net39,45647,757
 
Other Assets5,6265,376
 
Total Assets105,781112,314
 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt2,4001,379
Trade accounts payable2,3082,244
Accrued and other current liabilities8,5149,455
Income taxes payable1,2431,167
Dividends payable1,1761,189
6% Mandatory convertible preferred stock, $1 par value Authorized - 11,500,000 shares issued and outstanding - 855,422 shares0207
 
Total current liabilities15,64115,641
 
Long-Term Debt15,48216,095
 
Deferred Income Taxes and Noncurrent Liabilities17,85319,093
 
Merck & Co., Inc. Stockholders' Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,576,948,356 shares - 2010; 3,562,528,536 - 20091,7881,781
Other paid-in capital40,70139,683
Retained earnings37,53641,405
Accumulated other comprehensive loss(3,216)(2,767)
 
Stockholders' equity before deduction for treasury stock76,80980,102
Less treasury stock, at cost: 494,841,533 shares - 2010; 454,305,985 shares - 200922,43321,044
 
Total Merck & Co., Inc. stockholders' equity54,37659,058
 
Noncontrolling Interests2,4292,427
 
Total equity56,80561,485
 
Total Liabilities and Stockholders' Equity105,781112,314
 
External Links 
MERCK & CO., INC. (MRK) Fiscal Year 2010
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip